title: Development of coated nifedipine dry elixir as a long acting oral delivery with bioavailability enhancement.
abstract: To develop the long acting nifedipine oral delivery with bioavailability enhancement, a nifedipine dry elixir (NDE) containing nifedipine ethanol solution in dextrin shell was prepared using a spray-dryer, and then coated nifedipine dry elixir (CNDE) was prepared by coating NDE with Eudragit acrylic resin. The physical characteristics and bioavailability of NDE and CNDE were evaluated, and then compared to those of nifedipine powder. NDE and CNDE, which were spherical in shape, had about 6.64 and 8.68-8.75 μm of geometric mean diameters, respectively. The amount of nifedipine dissolved from NDE for 60 min increased about 7- and 40-fold compared to nifedipine powder in pH 1.2 simulated gastric fluid and pH 6.8 simulated intestinal fluid, respectively. Nifedipine released from CNDE was retarded in both dissolution media compared with that from NDE. After oral administration of NDE, the C(max) and AUC(0→8h) of nifedipine in rat increased about 13- and 7-fold, respectively, and the Tmax of nifedipine was reduced significantly compared with those after oral administration of nifedipine powder alone. The AUC(0→8h) and T(max) of nifedipine in CNDE increased markedly and the C(max) of nifedipine in CNDE was significantly reduced compared to those in NDE. It is concluded that CNDE, which could lower the initial burst-out plasma concentration and maintain the plasma level of nifedipine over a longer period with bioavailability enhancement, might be one of potential alternatives to the marketed long acting oral delivery system for nifedipine.
authors.affiliation: College of Pharmacy, Seoul National University, Seoul 151-742, Korea.
authors.forename: Jae-Yoon
authors.initials: JY
authors.lastname: Choi
authors.forename: Su-Eon
authors.initials: SE
authors.lastname: Jin
authors.forename: Youmie
authors.initials: Y
authors.lastname: Park
authors.forename: Hyo-Jong
authors.initials: HJ
authors.lastname: Lee
authors.forename: Yohan
authors.initials: Y
authors.lastname: Park
authors.forename: Han-Joo
authors.initials: HJ
authors.lastname: Maeng
authors.forename: Chong-Kook
authors.initials: CK
authors.lastname: Kim
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002849:Chromatography, Gas; D003692:Delayed-Action Preparations; D003890:Desiccation; D003912:Dextrins; D005079:Excipients; D008297:Male; D008855:Microscopy, Electron, Scanning; D009543:Nifedipine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010316:Particle Size; D019999:Pharmaceutical Solutions; D011109:Polymethacrylic Acids; D011208:Powders; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility
chemical_list: D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D003912:Dextrins; D005079:Excipients; D019999:Pharmaceutical Solutions; D011109:Polymethacrylic Acids; D011208:Powders; C038300:methylmethacrylate-methacrylic acid copolymer; D009543:Nifedipine